{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'Table 9.2', 'Clinical Activity Score (CAS) Assessment', 'Item 1', 'Description', '1.', 'Spontaneous orbital pain.', '2.', 'Gaze evoked orbital pain.', '3.', 'Eyelid swelling that is considered to be due to active (inflammatory phase) TED/GO.', '4.', 'Eyelid erythema.', '5.', 'Conjunctival redness that is considered to be due to active (inflammatory phase) TED/GO (ignore', '\"equivocal\" redness).', '6.', 'Chemosis.', '7.', 'Inflammation of caruncle or plica.', '1 Each item is scored (1=present; 0=absent) and scores for each item are summed for total score.', 'To promote consistency in data collection across clinical trial sites, all Investigators will be', \"provided with training and copies of the Clinical Manifestations chapter in Graves' Orbitopathy:\", 'A Multidisciplinary Approach - Questions and Answers [Dickinson, 2010]. Except when strictly', 'unavoidable, the same observer should conduct each CAS evaluation for the full duration of the', 'study.', '9.5.1.3 Clinical Measures of Severity', 'Based on the EUGOGO Consensus Statement [Bartalena et al, 2008; Wiersinga et al, 2006], the', 'following items will be assessed on Day 1 and Weeks 6, 12, 18, and 24 (or PW) during the', 'Treatment Period, and at Months 7,9, and 12 (or PW) during the Follow-Up Period (Table 9.3).', 'Except when strictly unavoidable, the same observer should conduct each evaluation of severity', 'measure for the full duration of the study.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 83 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'Table 9.3', 'Clinical Measures of Severity', 'Item and Assessment Scale', 'Minimum change required for classifying', 'overall response', 'Exophthalmos (measured in mm using the same Hertel', 'Decrease > 2 mm', 'exophthalmometer provided by the Sponsor for consistency in', 'measurement and same intercanthal distance for each individual', 'patient)', 'Lid aperture (distance between the lid margins in mm with the', 'Decrease > 2 mm', 'patient looking in the primary position, sitting relaxed and with', 'distant fixation)', 'Swelling of the eyelids (absent, mild, moderate, severe)', 'Decrease > One grade', 'Redness of the eyelids (absent, present)', 'Decrease One grade', 'Redness of the conjunctiva (absent, present)', 'Decrease > One grade', 'Conjunctival edema (absent, present)', 'Decrease > One grade', 'Inflammation of the caruncle or plica (absent, present)', 'Decrease > One grade', 'Subjective diplopia score', 'Decrease > One grade', '0=no diplopia;', '1=intermittent (diplopia in primary position of gaze, when tired or', 'when first awakening);', '2=inconstant (diplopia at extremes of gaze);', '3=constant (continuous diplopia in primary or reading position)', 'Eye muscle involvement (ductions in degrees)', 'Increase > 8\u00b0 in at least one direction of gaze', 'Corneal involvement (absent/punctate keratopathy/ulcer)', 'Decrease > One grade', 'Optic nerve involvement', 'Change of best corrected visual acuity by > 2', 'Best corrected visual acuity', 'lines on Snellen chart, or substantial color', 'Color vision', 'vision change, or significant change of visual', 'Optic disc', 'fields, or significant change in optic disc', 'Relative afferent pupillary defect (APD) (absent/present)', 'appearance, or (Dis-) appearance of relative', 'Visual fields if optic nerve compression is suspected.', 'afferent pupillary defect', '9.5.1.3.1 Motility Restriction - Details for Measurement', 'Motility is examiner assessed by estimating the degrees of restriction in eye movements. It will', 'be assessed at the same time points as the Clinical Measures of Severity.', 'Monocular excursions in horizontal and vertical directions of gaze are recorded using the light', 'reflex (LR) test [Dolman et al, 2012].', 'The clinician will shine a pen light in line with the eye being examined in ambient room light', \"and observe the subject's eye along the light's axis. The subject will be asked to look in the\", '4 cardinal directions and the position of the light reflex is viewed on the surface of the cornea. If', 'the light touches the limbus, the eye is assessed to be turned 45 degrees, if half way between the', 'limbus and pupil edge, the eye is assessed at 30 degrees, and if it is at the pupil edge, it was', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 84 of 118']\n\n###\n\n", "completion": "END"}